References
- Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96:4240–4245.
- Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006;30:262–265.
- Pene F, Claessens YE, Muller O, et al Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002;21:6587–6597.
- Peterson TR, Laplante M, Thoreen CC, et al DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:873–886.
- Knobloch J, Schmitz I, Gotz K, Schulze-Osthoff K, Ruther U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 2008;28:529–538.
- Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res 2008;14:3052–3059.
- Gao S, Yang XJ, Zhang WG, Ji YW, Pan Q. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl) 2009;122:1260–1266.
- Walker BA, Leone PE, Jenner MW, et al Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006;108:1733–1743.
- Jenner MW, Leone PE, Walker BA, et al Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 2007;110:3291–3300.
- Dickens NJ, Walker BA, Leone PE, et al Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010;16:1856–1864.